[ad_1]
- The recovery team has announced that it will test colchicine as a potential treatment for severe cases of COVID-19.
- Recovery is a massive coronavirus drug trial in the UK tasked with discovering the vital properties of dexamethasone.
- Along with colchicine, which is used for the treatment of gout, the recovery trial is also currently studying aspirin, azithromycin, and several other drugs.
If there is one good thing about 2020, it’s the incredible scientific effort that has gone into studying the novel coronavirus. Researchers have conducted all kinds of experiments to learn as much as possible about the virus. Hundreds of teams have come up with vaccine ideas, dozens of which have now reached the final stages of testing. A handful of these drugs will soon be in use in the general population.
In addition, dozens of existing drugs have been studied as potential therapies against COVID-19. Preventing serious infection with a vaccine only solves part of the COVID-19 puzzle; vaccines will not work on people who are already infected and are fighting the disease. Doctors have done an incredible job of finding ways to reduce the worsened immune response in some patients and save more lives. And doctors aren’t at a loss for ideas on how to treat patients with complications.
The latest attempt comes from a well-known British essay. The Recovery trial has already produced results, including the discovery that dexamethasone may save some patients who end up experiencing life-threatening complications. The team recently announced that they will study low-dose aspirin in the treatment of COVID-19, and the latest venture involves colchicine, a drug already widely available and commonly used to treat gout.
BGR’s best deal of the day
FDA Approved Powecom KN95 Masks NIOSH Certified to Perform Even Better Than 3M N95 Masks are at a reduced price for Black Friday! List of prices:$ 23.50 Price:Was $ 45, now $ 26.25 You save:$ 1.19 (5%) 
Available on Amazon, BGR may receive a commission
Colchicine is an anti-inflammatory drug and doctors hope it can lower the heightened immune response some patients experience. The recovery team has announced that it will study the drug in a large randomized trial. The drug will be administered randomly to at least 2,500 hospitalized patients, Reuters reports. 2,500 additional patients will receive standard care only.
“Colchicine is an interesting drug to evaluate in the recovery trial because it is very well understood, inexpensive and widely available,” said Professor Peter Horby of the University of Oxford. The physician is the trial’s co-chief investigator. “If that works, it would be another COVID-19 treatment that could be used immediately around the world, even in the poorest countries.”
“Inflammation plays a major role in COVID-19, and we have already shown that treatment with an anti-inflammatory drug, dexamethasone, can reduce the number of deaths in the most seriously ill COVID-19 patients,” Professor Martin Landray said in a statement. “Colchicine is widely used to treat gout and other inflammatory conditions such as pericarditis. By including colchicine in the RECOVERY trial, we will be able to determine if it is helping to fight the worst consequences of COVID-19. “
Researchers plan to use a dose of 1000 micrograms of colchicine at first, then 500 micrograms every 12 hours for a total of 10 days or until discharge. The researchers will then measure the 28-day death rate. They will also examine the impact on hospital stays and the need for ventilation. The study may take several months to produce results, as it all depends on recruitment rates.
BGR’s best deal of the day
Cyber Monday Offer: Save 15% on FDA Approved Powecom KN95 Masks NIOSH Proven to Work Better Than 3M N95 Masks List of prices:$ 23.50 Price:$ 22.31 You save:$ 1.19 (5%) Available on Amazon, BGR may receive a commission
Like dexamethasone, colchicine is affordable and widely available. The drug costs $ 124 for 30 capsules, which is much cheaper than remdesivir, one of the more well-known drugs approved for treatment with COVID-19. Remdesivir may speed recovery, but it cannot save lives, as the WHO recently warned against using the investigational drug.
Dexamethasone, on the other hand, can reduce inflammation and save the lives of people with severe disease progression, often requiring intensive care, oxygen therapy, and even mechanical ventilation.
Along with aspirin and colchicine, the recovery team is studying tocilizumab, another anti-inflammatory drug that has shown mixed results this year – the latest study on the subject has shown a lot of promise for the therapy. The Recovery trial also evaluates the efficacy of azithromycin, convalescent plasma from survivors, as well as Regeneron’s REGN-COV2 monoclonal antibody combo (casirivimab and imdevimab), which was recently approved for use by Regeneron. emergency in the United States. Previous recovery studies include hydroxychloroquine and the anti-HIV lopinavir / ritonavir combination, but none have been shown to be effective treatment for coronaviruses.
Chris Smith started writing about gadgets as a hobby, and before he even knew it he was sharing his take on tech with readers around the world. Whenever he doesn’t write about gadgets, he miserably fails to walk away from them, although he desperately tries. But that’s not necessarily a bad thing.
[ad_2]
Source link